Drug Trial Radar · NCT06831344
A Study to Evaluate Two Vonoprazan Orally Disintegrating Tablet Formulations Administered Without Water or Mixed With Water and Administered Via a Syringe Relative to the Vonoprazan Tablet in Healthy Participants
Last checked: Nov 20, 2026Latest source record: Dec 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
25
Actual
Start
Feb 14, 2025
Primary completion
Apr 5, 2025
Study completion Apr 10, 2025
Sponsor
- Lead sponsor
- Phathom Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of this study is to assess the bioavailability (BA) of a single oral dose of two vonoprazan orally disintegrating tablet formulations (ODT-1 or ODT-2) administered without water or mixed with water and administered via a syringe relative to the vonoprazan tablet in healthy participants.
Conditions
- Healthy Volunteers
Interventions
Vonoprazan ODT-1 or ODT-2 without WaterDrug
Vonoprazan will be administered orally as an ODT-1 or ODT-2 without water
Vonoprazan ODT-1 or ODT-2 with WaterDrug
Vonoprazan will be administered orally as an ODT-1 or ODT-2 with water via a syringe
Vonoprazan (Reference)Drug
Vonoprazan will be administered orally as a tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Observed Drug Concentration (Cmax) of VonoprazanTime frame: Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose
- Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Last Quantifiable Concentration (AUC0-t) of VonoprazanTime frame: Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose
- AUC From Time 0 Extrapolated to Infinity (AUC0-inf) of VonoprazanTime frame: Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
7551 Metro Center Dr Ste 200
Austin, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.